Health
Drug-Resistant Superbugs Kill Thousands Across Europe, Threatening Medical Progress
Drug-resistant infections are causing more than 35,000 deaths annually across Europe, and health authorities warn the growing threat could undo years of medical progress.
Antimicrobial resistance (AMR) occurs when bacteria, viruses, and other pathogens evolve to survive existing treatments, making infections harder to treat. The resistance also increases risks for patients undergoing procedures such as organ transplants, chemotherapy, and complex surgeries.
The European Centre for Disease Prevention and Control (ECDC) released estimates on Tuesday showing that AMR contributes to tens of thousands of fatalities each year across the European Union, Iceland, Liechtenstein, and Norway. The agency described a “perfect storm” driving the rise in resistance: an ageing population more vulnerable to infections, cross-border spread of drug-resistant pathogens, overuse of antibiotics by doctors and patients, and gaps in infection prevention and control measures.
“We must ensure that no one in Europe is left without an effective treatment option,” said Dr. Diamantis Plachouras, who leads the ECDC’s work on AMR and healthcare-associated infections.
The EU Council set five targets in 2023 to combat AMR, including curbing overall antibiotic use, ensuring at least 65 per cent of antibiotics are first-line treatments, and reducing bloodstream infections from three drug-resistant bacteria. The new report shows that Europe has met only one of these goals.
Bloodstream infections caused by meticillin-resistant Staphylococcus aureus (MRSA) have fallen by 20.4 per cent since 2019, surpassing the target reduction of 15 per cent. However, new bloodstream infections from carbapenem-resistant Klebsiella pneumoniae have risen by over 60 per cent, despite a target reduction of 5 per cent. Highly resistant strains of Escherichia coli (E. coli) have also increased by more than 5 per cent, against a reduction goal of 10 per cent.
Antibiotic use across Europe has risen, including drugs meant only as last-resort treatments. This trend, combined with a shortage of new antibiotics for high-priority pathogens such as carbapenem-resistant gram-negative bacteria (CR-GNB), has left health systems struggling to keep infections under control.
ECDC Director Dr. Pamela Rendi-Wagner said urgent action is needed to curb resistance and support medical advances. “Tackling AMR requires critical innovation,” she said. She called for increased investment in promoting responsible antibiotic use, strengthening infection prevention, and developing new drugs.
Experts warn that without immediate action, Europe could face mounting deaths and rising healthcare costs. AMR is now seen not just as a clinical challenge but as a public health crisis that threatens the safety of routine medical treatments and the ability of hospitals to manage serious infections effectively.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
